dopamine quinone has been researched along with Idiopathic Parkinson Disease in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavanya, R; Nagashanmugam, KB; Ponnusamy, S; Prabhu, N; Priyatharshni, S; Sivakumar, P | 1 |
| Dijkstra, JM; Ito, S; Nagatsu, T; Nakashima, A; Riederer, P; Wakamatsu, K; Watanabe, H; Wulf, M; Youdim, M; Zecca, L; Zucca, FA | 1 |
| Ho, PGH; Lei, Z; Saw, WT; Tan, EK; Wang, H; Xie, SP; Yi, Z; Zhou, ZD | 1 |
| Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y | 1 |
| Badillo-Ramírez, I; Rivas-Arancibia, S; Saniger, JM | 1 |
| Dukes, AA; Hastings, TG; Hauser, DN; Mortimer, AD | 1 |
| Baranyi, M; Chai, CL; Dunkel, P; Frau, L; Gölöncsér, F; Huleatt, PB; Khoo, ML; Kittel, Á; Kulcsár, S; Mátyus, P; Morelli, M; Otrokocsi, L; Pinna, A; Porceddu, PF; Sperlágh, B | 1 |
| Berman, SB; Hastings, TG; Van Laar, VS | 1 |
| Asanuma, M; Miyazaki, I | 1 |
| Fujimura, T; Hattoria, N; Kubo, S; Mochizuki, H; Taka, H; Wanga, M; Yoritaka, A | 1 |
| Coleman, RA; Green, RL; Lorenz, AN; Sass, MB | 1 |
| Hastings, TG | 1 |
| Arduini, I; Bisaglia, M; Bubacco, L; Mammi, S; Soriano, ME | 1 |
| Belluzzi, E; Beltramini, M; Bisaglia, M; Bubacco, L; Lazzarini, E; Tabares, LC | 1 |
| Asanuma, M; Miyazaki, I; Ogawa, N | 1 |
| Hattori, N; Machida, Y; Noda, K | 1 |
| Cascio, M; Dukes, AA; Hastings, TG; Van Laar, VS | 1 |
| Roskoski, R; Stokes, AH; Vrana, KE; Xu, Y | 1 |
| Chung, BS; Kang, CD; Kim, KW; Kim, SH; Lee, HJ; Lee, HW; Um, JH | 1 |
| Appel, SH; He, Y; Le, W; Ortiz, I; Rowe, D; Xie, W | 1 |
6 review(s) available for dopamine quinone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
Topics: alpha-Synuclein; Antioxidants; Dopamine; Humans; Parkinson Disease | 2023 |
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Topics: Catecholamines; Cysteine; Dopaminergic Neurons; Humans; Melanins; Norepinephrine; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2023 |
5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
Topics: alpha-Synuclein; Biomarkers; Dopamine; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Humans; Metabolic Networks and Pathways; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Pars Compacta; Sulfur | 2019 |
Dopaminergic neuron-specific oxidative stress caused by dopamine itself.
Topics: Animals; Disease Models, Animal; Dopamine; Free Radicals; Humans; Neurons; Oxidative Stress; Parkinson Disease | 2008 |
Toxic effects of dopamine metabolism in Parkinson's disease.
Topics: Aldehydes; alpha-Synuclein; Animals; Dopamine; Humans; Levodopa; Mitochondria; Oxidative Stress; Parkinson Disease | 2009 |
Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.
Topics: Animals; Dopamine; Dopamine Agents; Free Radicals; Humans; Levodopa; Monophenol Monooxygenase; Neurotoxicity Syndromes; Parkinson Disease | 2003 |
14 other study(ies) available for dopamine quinone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
Topics: Animals; Dopamine; Dopaminergic Neurons; Drosophila; HEK293 Cells; Humans; Nerve Degeneration; Parkinson Disease; Plant Extracts; Polyphenols; Tea | 2019 |
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone | 2020 |
Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4.
Topics: Animals; Blotting, Western; Dopamine; Dopaminergic Neurons; Glutathione Peroxidase; In Vitro Techniques; Parkinson Disease; PC12 Cells; Phospholipid Hydroperoxide Glutathione Peroxidase; Rats | 2013 |
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Rats, Wistar; Substantia Nigra | 2016 |
Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone.
Topics: Animals; Cell Death; Dopamine; Dopaminergic Neurons; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Muscle Proteins; Parkinson Disease; PC12 Cells; Rats; Rotenone | 2016 |
A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Topics: alpha-Synuclein; Amyloid; Antiparkinson Agents; Computer Simulation; Dopamine; Gene Expression; Humans; Levodopa; Lewy Bodies; Lysosomes; Models, Neurological; Monoamine Oxidase Inhibitors; Neurotoxins; Parkinson Disease; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Systems Theory; Ubiquitin | 2009 |
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease.
Topics: Animals; Dopamine; Humans; Mitochondria; Neurons; Oxidation-Reduction; Parkinson Disease; Proteome; Substantia Nigra | 2009 |
Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease.
Topics: Animals; Dopamine; Glutathione; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Mitochondria, Liver; Mitochondrial Swelling; Models, Biological; NAD; Oxidative Stress; Parkinson Disease; Quinones; Spectrophotometry, Ultraviolet | 2010 |
Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease.
Topics: Catalytic Domain; Dopamine; Enzyme Activation; Humans; Kinetics; Manganese; Mitochondria; Mutation; Parkinson Disease; Protein Binding; Reactive Oxygen Species; Superoxide Dismutase | 2012 |
[Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation].
Topics: alpha-Synuclein; Animals; Apoptosis; Cells, Cultured; Dihydroxyphenylalanine; Dopamine; Humans; I-kappa B Proteins; Lewy Bodies; NF-KappaB Inhibitor alpha; Parkinson Disease; Phosphorylation; Ubiquitin-Protein Ligases | 2005 |
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease.
Topics: Animals; Brain; Dopamine; Male; Mitochondria; Mitochondrial Proteins; Oxidative Stress; Parkinson Disease; PC12 Cells; Proteomics; Rats; Rats, Sprague-Dawley | 2008 |
Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase.
Topics: Animals; Antioxidants; Chromatography, Gel; Dihydroxyphenylalanine; Dithiothreitol; Dopamine; Electrophoresis, Polyacrylamide Gel; Feedback; Glutathione; Monophenol Monooxygenase; NAD; Neoplasm Proteins; Nerve Tissue Proteins; Parkinson Disease; PC12 Cells; Plant Proteins; Precipitin Tests; Rats; Tyrosine 3-Monooxygenase | 1998 |
Antiapoptotic role of NF-kappaB in the auto-oxidized dopamine-induced apoptosis of PC12 cells.
Topics: Animals; Apoptosis; Cell Death; DNA; DNA-Binding Proteins; Dopamine; Genes, Dominant; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Pheochromocytoma; Rats; Transcription Factor RelA; Transfection | 2001 |
Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease.
Topics: Adult; Aged; Animals; Cell Membrane; Cells, Cultured; Cytokines; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Immunoglobulin Fab Fragments; Immunoglobulin G; Lipopolysaccharides; Mice; Mice, Knockout; Microglia; Middle Aged; Neurons; Nitric Oxide; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, IgG | 2001 |